🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Heidelberg
Clinical trial register · Germany

Clinical Trials in Heidelberg, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 115 Essen 57 Hamburg 56 Cologne 48 Dresden 48
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University Hospital Heidelberg50 AstraZeneca33 Janssen Research & Development, LLC27 Merck Sharp & Dohme LLC18 Hoffmann-La Roche17 Clear sponsor filter
Site location
Berlin115 Essen57 Hamburg56 Cologne48 Dresden48
All 184 locations
Target enrolment
to

Trials with a site in Heidelberg

33 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Active, closed
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM
NCT07608354Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
DrugsCliramitug·Eplontersen
AstraZeneca
Phase 2
326
Berlin, Cologne, Essen, Hamburg, Heidelberg, Homburg, München, Münster
2026-06-11
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Bonn, Essen, Freiburg im Breisgau, Fulda, Giessen, Hamburg, Hanover, Heidelberg
2026-06-11
Recruiting
NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care
NCT07424261Lupus Erythematosus, Systemic
AstraZeneca
Observational
125
Altenburg, Bad Bramstedt, Berlin, Braunschweig, Chemnitz, Erlangen, Heidelberg, Herne
2026-03-19
Recruiting
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
NCT07215702Sepsis, Acute Kidney Injury
DrugAZD4144
AstraZeneca
Phase 2
124
Aachen, Essen, Frankfurt, Greifswald, Heidelberg, Kiel, Leipzig, Münster
2026-02-10
Recruiting
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
NCT07155226Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes
DrugPosaconazole
AstraZeneca
Phase 1/2
84
Dresden, Frankfurt A. Main, Halle, Heidelberg, München, Ulm
2026-01-09
Recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336Endometrial Cancer, Malignant Solid Tumour
DrugsAdriamycin·Taxol·Doxorubicin·Paclitaxel
AstraZeneca
Phase 3
800
Amberg, Chemnitz, Dresden, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg
2025-08-01
Recruiting
UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
NCT06726720Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
AstraZeneca
Observational
300
Berlin, Dresden, Frankfurt am Main, Halle, Hamburg, Hanover, Heidelberg, Kassel
2024-12-16
Recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
DrugsVolrustomig·Adrucil·Paclitaxel·Cisplatin
AstraZeneca
Phase 2
257
Cologne, Frankfurt, Gauting, Großhansdorf, Hamburg, Heidelberg, Mainz, Münster
2024-08-22
Recruiting
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
NCT06549595Untreated Follicular Lymphoma
DrugsSurovatamig·R-Chop
AstraZeneca
Phase 3
1,018
Berlin, Deggendorf, Düsseldorf, Göttingen, Hamburg, Heidelberg, Jena, Karlsruhe
2024-08-07
Active, closed
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
NCT06346392Gastric Cancer, Gastroesophageal Junction Cancer
DrugsSonesitatug Vedotin·Ramucirumab·Trifluridine/Tipiracil·Apatinib
AstraZeneca
Phase 3
594
Berlin, Frankfurt, Göttingen, Hamburg, Heidelberg, Heilbronn, Leipzig, Marburg
2024-03-04
Recruiting
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
NCT06106945Multiple Myeloma
DrugsElranatamab·Pomalidomide·Dexamethasone
AstraZeneca
Phase 1/2
226
Essen, Freiburg im Breisgau, Hamburg, Heidelberg, Lübeck, Nuremberg, Tübingen, Würzburg
2023-12-05
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864Breast Cancer
DrugsDatopotamab deruxtecan·Durvalumab·Nab-paclitaxel·Gemcitabine
AstraZeneca
Phase 3
625
Düsseldorf, Essen, Georgsmarienhütte, Hamburg, Hanover, Heidelberg, Heilbronn, Leipzig
2023-11-23
Active, closed
A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice.
NCT05637112Systemic Lupus Erythematosus
AstraZeneca
Observational
551
Heidelberg, Erlangen, Bad Bramstedt, Schleswig-Holstein, Greifswald, Cologne, D Sseldorf, Herne
2023-02-27
Active, closed
A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
NCT05061134Melanoma
DrugsCeralasertib·Durvalumab
AstraZeneca
Phase 2
194
Berlin, Buxtehude, Heidelberg, Heilbronn, Kiel, Mainz, München, Regensburg
2022-08-11
Recruiting
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
NCT05417594Advanced Solid Malignancies
DrugsPalacaparib·Datopotamab deruxtecan·Trastuzumab deruxtecan·Temozolomide
AstraZeneca
Phase 1/2
695
Bayern, Berlin, Heidelberg, Mainz
2022-06-24
Active, closed
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
NCT05138133Lupus Nephritis
DrugAnifrolumab
AstraZeneca
Phase 3
363
Cologne, Dresden, Hanover, Heidelberg, Kirchheim, Mainz Am Rhein
2022-02-15
Active, closed
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
NCT05113251Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
DrugsHerzuma·Perjeta·Herceptin·Cytoxan
AstraZeneca
Phase 3
927
Augsburg, Berlin, Erlangen, Hamburg, Heidelberg, Kiel, Leipzig, Mönchengladbach
2021-10-25
Active, closed
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
NCT05104866Breast Cancer
DrugsVinorelbine·Eribulin·Datopotamab deruxtecan·Capecitabine
AstraZeneca
Phase 3
732
Heidelberg, Homburg, Leipzig, München, Ravensburg
2021-10-18
Active, closed
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
NCT04784715Breast Cancer; HER2-positive; Metastatic
DrugsPertuzumab·Trastuzumab deruxtecan·Trastuzumab
AstraZeneca
Phase 3
1,157
Berlin, Dresden, Erlangen, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg
2021-04-26
Active, closed
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
NCT04592913Gastrointestinal Neoplasms, Esophagogastric Junction
DrugDurvalumab
AstraZeneca
Phase 3
957
Berlin, Dresden, Frankfurt, Hamburg, Heidelberg, Heilbronn, Jena, Mainz Am Rhein
2020-11-17
Active, closed
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
NCT04305496Locally Advanced (Inoperable) or Metastatic Breast Cancer
DrugsCapivasertib·Fulvestrant
AstraZeneca
Phase 3
818
Dresden, Erlangen, Essen, Frankfurt, Gelsenkirchen, Hamburg, Hanover, Heidelberg
2020-04-16
Active, closed
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
NCT03847428Hepatocellular Carcinoma
DrugsAvastin·Durvalumab·Bevacizumab
AstraZeneca
Phase 3
908
Berlin, Bonn, Chemnitz, Cologne, Freiburg im Breisgau, Heidelberg, Leipzig, Lübeck
2019-04-29
Recruiting
An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia
NCT03813407Hyperkalaemia
DrugPumitamig
AstraZeneca
Phase 3
140
Berlin, Essen, Heidelberg
2019-04-02
Active, closed
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
NCT03833154Carcinoma, Non-Small-Cell Lung
DrugDurvalumab
AstraZeneca
Phase 3
724
Dresden, Göttingen, Halle, Hanover, Heidelberg, Homburg, Regensburg, Trier
2019-03-06
Active, closed
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT03703297Small Cell Lung Cancer
DrugsTremelimumab·Durvalumab
AstraZeneca
Phase 3
730
Berlin, Cologne, Freiburg im Breisgau, Gauting, Heidelberg, Mainz, Münster, Oldenburg
2018-09-27
Active, closed
Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
NCT03528694Non-muscle-invasive Bladder Cancer
DrugsBacillus Calmette-Guerin·Durvalumab
AstraZeneca
Phase 3
1,018
Berlin, Cologne, Duisburg, Hanover, Heidelberg, Marburg, Mettmann, Mühlheim An Der Ruhr
2018-05-14
Active, closed
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
NCT03334617Non-Small Cell Lung Cancer
DrugsVistusertib·Danvatirsen·Ceralasertib·Cediranib Maleate
AstraZeneca
Phase 2
528
Berlin, Esslingen a.N., Großhansdorf, Heidelberg
2017-12-18
Active, closed
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
NCT03298451Hepatocellular Carcinoma
DrugsSorafenib·Tremelimumab·Durvalumab
AstraZeneca
Phase 3
1,324
Aachen, Cologne, Essen, Hanover, Heidelberg, Leipzig, Mainz, München
2017-10-11
Active, closed
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
NCT03164616Non Small Cell Lung Cancer NSCLC
DrugsAbraxane·Tremelimumab·Durvalumab·Pemetrexed
AstraZeneca
Phase 3
1,186
Berlin, Essen, Freiburg im Breisgau, Gauting, Hamburg, Heidelberg, Immenhausen, Mainz
2017-06-01
Active, closed
Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
NCT03043872Small Cell Lung Carcinoma Extensive Disease
DrugsTremelimumab·Etoposide·Durvalumab·Cisplatin
AstraZeneca
Phase 3
987
Aachen, Berlin, Gauting, Gera, Hamburg, Heidelberg, Mainz, Regensburg
2017-03-27
Active, closed
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
NCT02516241Urothelial Cancer
DrugsTremelimumab·Durvalumab·Gemcitabine·Cisplatin
AstraZeneca
Phase 3
1,126
Düsseldorf, Erlangen, Hanover, Heidelberg, Jena, München, Münster
2015-11-02
Active, closed
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
NCT02453282Non-Small-Cell Lung Carcinoma NSCLC
DrugsTremelimumab·Durvalumab·Pemetrexed·Gemcitabine
AstraZeneca
Phase 3
1,118
Aachen, Bad Berka, Berlin, Freiburg im Breisgau, Gauting, Hamburg, Heidelberg, Hemer
2015-07-21
Active, closed
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
NCT01933932Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
DrugsPegylated G-CSF·Pegfilgrastim·Selumetinib·Docetaxel
AstraZeneca
Phase 3
510
Augsburg, Bad Berka, Cologne, Dortmund, Gerlingen, Großhansdorf, Halle, Heidelberg
2013-09-25
Rows per page Showing 1–33 of 33
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/heidelberg

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 33 of those studies with a site in Heidelberg that also match the filters currently applied.

How many clinical trials are recruiting in Heidelberg?

12 of the 33 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 0 have not yet opened recruitment, 21 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Heidelberg), 33 studies
PhaseStudiesRecruitingShare
Phase 321463.6%
Phase 26318.2%
Observational329.1%
Phase 1/2339.1%

Most active sponsors

Lead sponsors with the most studies (Heidelberg)
Lead sponsorStudiesRecruiting
AstraZeneca3312
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.